Summary. ]n Exp. ;, the efi·ect of treatment with a GnRH agonist on basal concentr3tions of serum testosterone and peak value:; of serum testosterone after administration of heG was determined. One group of adult male monkeys was treated with a low dose (5-10 ~g/day) and a second group with a high dose (25 ~g/clay) of a GnRH agonist for 44 weeks. Basal and peak testosterone concentrations were both significantly reduced by GnRH agonist treatment in all groups compared to untreated control animals, but tht: % rise in serum testosterone 3bove basal values in response to heG administration was unchanged by agonist treatment.
Introduction
Chronic administration of gonadotrophin-releasing hormone (GnRH) agonists causes azoospermia in monkeys and men (Akhtar et al., 1983a, b; Swerdloff el al., Bouchard et al., 1986) and ejaculatory response in monkeys (Mann et al., ]987) does not interfere with agonist-induced azoospermia. Arlminis.ration of GnRH antagonists also suppresses spermatogenesis in primates although the doses of antagonist required for this effect are much greater than for agonists (Weinbauer et al., 1984; Akhtar el al., 1985) . These developments suggest that GnRH analogues may be llseful for male contraception.
The mechanism of the antifertility effects of GnRH analogues in primates remains undefined. GnRH agonists reduce the lutei'lizi.l£, hormone (LH) and testo~terone response to GnRH (Akhtar el al., ]983b; Mann el al., 1985, 19.s7) , presumably by down-regulating pituitary GnRH receptors, as reported for rats (Heber et al., 1982) . GnRH antagonists bind with high affinity to GnRH receptors in the pituitary, preventing binding by GnRH (Clayton el al., 1982) . In the rat, these analogues also directly inhibit gonadal steroidogenesis (Hsueh & Erickson, 1979; Clayton el al., 1980; Hsueh el a!., 1981; Sharpe & Cooper, 1982a , b, 1987 Sharpe, 1982; Spona el al., 1985) . However, most evidence does not support a gonadal site of action of these analogues in primates. GnRH agonist treatment does not abolish the testicular re!>ponse to LH or hCG in primates (Mann el al., 1984; Schnison el al., 1984; Heber el 01.,1984; Evans el ul., 1984) , and GnRH receptors were not demonstrated on the primate gonad (Asch e/ al., 1981; Clayton & Huhtaniemi, 1982) .
Evidem~e for a direct effect ofGnRH or GnRH-like peptides on the primate gonad is supported by findings that the seminiferous tubules of the stump-tailed macaque contain low-affinity GnRH-binding sites and GnRH-like bioiogiclli acivity, and human seminal plasma has GnRH-like immunoactivity (Sharpe el 01., 1981; Swerdloff el al., 1984) . In addition, the presence of a GnRH agonist inhibitl!d progesterone secretion from cultured human granulosa cells (Tureck el al., 1982) . Progesterone secretion was normal with simultaneous incubation with a GnRH antagonist (Tureck el al., 1982) . These results clearly indicate that the question about a direct effect of GnRH agonists on the primate gonad has 1I0t been resol\'~d.
In this study, we tested the hypothe~is that there is a direct effect of GnRH analogues on the testis of the rhesus monkey. We examined the effect of: (I) chronic GnRH agonist administration (44 ... :eeks) on the testicular response to a low dose ofhCG, (2) acute infusion ofa GnRH agonist or antagonist into the te:;ticular artery on testosterone release into the testicular vein in adult monkeys and (3) in-vitro incubation of monkey testicular interstitial cells with a GnRH agonist or antagonist on basal and hCG-stimulated testosterone production.
Materials and Methods
The 23 adult male rhesus monkeys (Mawca mu!al/a) used in lhis study were housed under a 12-h Iight:12-h dark lighting schedule (lights on: 06:00 h) at 20·-23°C.
E.(perimenr I: effect of chronic GnRIl agonist administration on the response to "eG. Ten monkeys were allocated randomly to two groups Group I animals were treated continuously with a GnRH agonist (o-Trp6-N-alpha-MeLeu 7-desGlylo-Pr0 9 -NHEt-GnRH; Wyeth Laboratories, Philadelphia, PAl, 5llg/day for 24 weeks followed by a dose of 10 Ilg/day of the same agonist for 20 weeks, using an osmotic mini pump as previously described (Mann et al., 1985 (Mann et al., , 1987 . The dose of agonist was doubled from 5 to 10 Ilg/day after 24 weeks because the 5llg/day dose was not effective in reducing sperm counts (Mapn et al., 1987) . Group 2 monkeys received 251lg agonist/day for 44 weeks. Pumps were replaced at 4-week intervals. All animals were injected Lv. with 50 Lu. hCG during the control (pretreatment) period and at the end of 44 weeks of agonist administration. Blood samples were taken 15 min before and at 0, 30, 60 and 120 min after hCG administration fOl determin:lIion of testosterone by radioimmunoassay.
EXl'l'rim('nt 2: influence of acute infimon 0/ a GnR 1/ agonist or alltago"ist ill10 the testicular artery on serumtestosterolle cOllcentrations ill tcstiClilar !'ein. Eighteen adult male monkeys w,'rc used with each animal serving as its own control. Animals were anaesthetized with 30 mg kctamine HCI/kg and prepared for abdominal surgery under sterile conditions. A midline incision was made in the abdominal region and the inguinal canal identified on one side of the animal. The GnRH agonist (100 or 400 ng), a GnRH antagonist (4Ilg; Ac-o-pCIPhe-o-Trp-Ser-Tyr-o-ArgLeu-Arg-Pro-o-Ala-NH 2 'CH l COOH; Organon, Oss, The Netherlands) or saline (0·154 M-NaCI) was infused into the testicular altery (proximal to its involvement with the pampiniform plexus) over a I-min period, and blood samples were taken from the testicular (0·5 ml) and fr;moral veins (4 ml) before and at IS, 30, 60 and 120 min after administration of the agonist for testosterone and LH determination. '\nalgesics were administered during the immediate post-surgical period. Aft~r a 2-3-mol1!h recovery period, animals were subjected to the identical procedure on the other f/:stis.
Experiment 3: effect of GIIRH '1gollist or antagonist treatment on testOJterolle production from mOllkey testicular interstitial cclls. Testicul .. r interstitial cells were prepared from 2 sexually mature mJle monkeys (3'5 and 12 years old). The testes were decapsulated and the remaining tissue was minced into small pieces. The tissue was then incubated in Me'lium 199 (pH 7·4; GIBCO, Grand Island, NY, USA) containing 1·0 109 collagenase/ml and 100 Lu. pcnicillinstreptomycin/ml in 3 ~ilaking waler bath at 34'C for 45 min under an atmosphere of 5% CO 2 :95% 02' The cell suspension was then filtered through nylon (Nit~x, mesh no. HD3-1 00, Tetko Inc., Elmsforce, NY, USA) and washed 3 times with Medium 199 without collagenase followed each time with centrifugation (400g for 5 min at 4°C). Cells were counted with a haemocytometer and viability was assessed with trypan blue. Cells were rediluted to 10 7 cells per ml in Medium 199 containing 0'1 mM-isobutyl-l-mr.thylxanthine.
In Exp. 3A, cells (10 6 ) were incubated with 0, 10-9 , 10-7 or 10-' M agonist in the absence or presence ofhCG (50, 250 or 1000 J.lLu.) for 24 hat 34"C under an atmosphere of 5% CO 2 :95% 02 in a shaking water bath. In Exp. 38, the agonist was replaced with 10 -9, 10 -7 and 10 -, M antagonist in the presence or absence ofhCG. Viability of cells was reassessed at the end of the incubation period. Cells were removed by centrifugation and testosterone concentration was determined in the incubation medium.
Assays. Serum concentrations of LH were measured using the mouse interstitial cell bioassay (Van Damme et al., 1974) . A rhesus monkey pituitary gonadotrophin standard (LER 1909-2) provided by the National Institutes of Diabetes and Diseases of the Kidney was used as the reference preparation. The intra-and interassay coefficients of variation were 11·2% and 14·7% respectively. The usable range of the LH bioassay standard curve was from 0·2 to 10 J.lg/ml. Serum testosterone concentrations were measured by radioimmunoassay as described in detail previously (Perachio et al., 1977) . The intra-and interassay coefficients of variation were 4·8% and 6·7% respectively. The usable portion of the testosterone standard curve was from 2 to 50 nmol/I. Statistical analysis. Data from Exps I and 2 were evaluated by a one-way analysis of variance (agonist treatment) with repeated measures (blood samples over lime) followed by the least significant difference test for multiple comparison~. In Exp. 3, data were evaluated by a two-way analysis of variance (agonist or antagonist treatment in the presence (r absence of hCG).
Results
Experiment J: effect of chronic GnRH agonist administration on the response /0 hCG Basal serum concentrations of testosterone were reduced in adult male monkeys in Group I and 2 compared to basal values during the control (pretreatment) period (Fig. I) . The peak serum testosterone concentration after an i.v. bolus of hCG was <40% of the control peak in Group 1 (P < 0·001) and < 30% in Group 2 (P < 0·001) (Fig. I) . However, when th(; lower basal values of testosterone in Groups I and 2 after agonist treatment were considered, the overall % increase of testosterone in response to hCG after agonist treatment in Groups I and 2 (666% ± 117 and 892% ± 436) did not differ from the control iesponse (652% ± 97). 
. influence of acute infusion of GnRH agonist or antagonist into the testicular artery on testosterone concentrations in the testicular andfemoral veins
Infusion of 100 or 400 ng GnRH agonist into the testicular artery failed to change testosterone concentrations in the testicular vein or systemic circulation over the next 2 h ( Table I) . The infusion of 4 Jlg GnRH antagonist also failed to influence testicular secretion of testosterone into the testicular vein (Table 1) . 
Values are mean ± s.e.m.; N = 6 for each GnRH analogue tr:ated group and each animal served as its own control.
Experiment 3: effect of a GnRH agonist or antagonist on testosterone production from monkey testicular interstitial cells ill vitro
As shown in Table 2 , incubation of testicular interstitial cells with 10-9 , 10-7 or 10-S M-GnRH agonist or antagonist failed to alter the amount of testosterone in the incubation medium after 24 h; J l ~ Direct gonadal effects of a Gr RH agonist 93 testosterone production ranged from 4·4 and .. ·7 pmol in Exp. 3A and 1·0 to 1·2 pmol in Exp. 3B. Untreated interstitial cells showed a dose-related increase (P < 0'001) in testosterone production when incubated with increasing doses of hCG (50-1000 Ili.u.) in Exps 3ft.. and 3B. While basal testosterone production was lower in Exp. 3B than in Exp. 3A, the overall respu;;e of cells (based on the % increase over basal values) to hCG did not differ between the two experiments (743% and 745%). The response of these cells to hCG was not affected by the presence of the GnRH agonist or antagonist in the incubation medium. 
Discussion
It has been ckarly established that GnRH analogues hilVe direct effects on testicular function in the rat. In hypophysectomized rats, GnRH agonists inhibited steroidogenesis, reduced the responsiveness to LH, and blocked FSH induction or LI-l receptors on Leydig cells (Bambino et al., 1980; Hsueh et al., 1981) . In-vitro incubation or te.;ticular interstitial or purified Leydig cells with GnRI1 agonist had a biphasic effect on testosterone production. Acutely. GnRH agonists increased testosterone production. However, the effect on testicular steroidogenesis was inhibitory in long··term incubations (24-27 h) (Hsuch et al., 1981; Sharpe & Cooper, 1982a) . Binding sites for GnRH were reported on rat Leydig cells (Hsueh & Erickson, 1979; Clayton et al., 1980) , and GnRH·like factors have been demonstrat~d in the rat testis (Sharpe et al., 1981; Swerdloff et al., 1984) . These data support the hypothesis that there is a GnRH-like gonadal peptide involved in modulating testicular steroidogenesis in the rat testis.
The results reported here do not demonstrate a direct effect of a GnRH agonist or antagonist on testicular steroidogenesis in the primate testis. Chronic GnRH agonist treatment for 44 weeks inhibited spermatogenesis and redllced bast! I concentrations of testosterone (Mann et al., 1987) , but failed to alter the testicular testosterone response (based on the % increase of ~erum testosterone after hCG to the basal testosterone value) of these animals to a low dose ofhCG. However, absolute peak concer·traiions of testosteront after hCG administration were lower in agonisttreated animals than they were during the control period.
Infusion of 100 or 400 ng GnRH agonist or 4 ~g antagonist directly into the testicular artery did n;)t significantly alter testosterone concentrations in the testicular vein over the next 2 h. However, serum LH concentrations in animals treated wil.h 400 ng agonist were slightly elevated 15 and 30 min after agonist administration, suggesting that this dose of agonist approaches levels that would stimulate pituitary LH secretion, and therefore, testicular testosterone secretion indirectly.
Finally, in-vitro incubation of testicular interstitial cells from sexually mature male monkeys with the GnRH agonist or antagonist (10-9 to 10-3 M) for 24 h did not affect either testosterone production or the testosterone response to hCG stimulation. These results do not rule out the possibility that shor;er or longer term incubations of the cells with the analogucs would have influenced steroidogenesis. However, GnRH agonist treatment of male monkeys for 44 weeks did not alter the testicular testosterone response to a low dose of hCG in vivo. Therefore, the in-vivo and in-vitro evidence from the pre~ent study dot'S not support the hypothesis that GnRH analogues directly alter testicular stei·o;dogenesis.
The results reported h~re provide the first direct evidence in vivo and in vitro that GnRH analogues do not directly alter testicular steroidogenesis in primates. These data are in agreement with a recent report that showed chronic GnRH agonist treatment for I year of men with prostatic cancer resulted in an inhibition of the production of.1. 4 and .1. 3 steroids in the testis. This inhibition was overcome by treatment with exogenous :lCG \~ajfer et al., 1987) . Thus, most evidence does not support the hypothesis that the testis is a site for the inhibitory effects of GnRH agonists on gonadal function. Nevertheless, there is a need to be cautious. Data continue to accumulate suggesting the presence of a GnRH-like protein in the primate gonad (human ovary) (Aten et al., 1987) . Moreover, while monkey testicular interstitial cells incubated for 24 h with a GnRH agonist ,r antagonist faiied 10 show any change in testosterone prod uction in the present study, it is possible that more chronic treatment with the analogues would have altered either basal testosterone secretion or thc response of these cells to hCG.
